Статус неизвестен
Фаза II
Армения
YH001 + Toripalimab · Eucure (Beijing) Biopharma Co., Ltd
An Open-Label, Non-Randomized, Multi-center Phase 2 Study of YH001 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) and Hepatocellular Carcinoma (HCC)